C5a is not involved in experimental autoimmune myasthenia gravis pathogenesis
- 30 May 2008
- journal article
- Published by Elsevier BV in Journal of Neuroimmunology
- Vol. 196 (1), 101-106
- https://doi.org/10.1016/j.jneuroim.2008.03.007
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Myasthenia Gravis Thymus: Complement Vulnerability of Epithelial and Myoid Cells, Complement Attack on Them, and Correlations with Autoantibody StatusThe American Journal of Pathology, 2007
- Genetic evidence for the involvement of Fcγ receptor III in experimental autoimmune myasthenia gravis pathogenesisJournal of Neuroimmunology, 2006
- C5a and Fc receptors: a mutual admiration societyJCI Insight, 2006
- Cell-derived anaphylatoxins as key mediators of antibody-dependent type II autoimmunity in miceJCI Insight, 2006
- C5a Receptor Deficiency Attenuates T Cell Function and Renal Disease in MRLlpr MiceJournal of the American Society of Nephrology, 2005
- IL-1 Receptor Antagonist-Mediated Therapeutic Effect in Murine Myasthenia Gravis Is Associated with Suppressed Serum Proinflammatory Cytokines, C3, and Anti-Acetylcholine Receptor IgG1Published by The American Association of Immunologists ,2005
- Genetic Evidence for Involvement of Classical Complement Pathway in Induction of Experimental Autoimmune Myasthenia GravisPublished by The American Association of Immunologists ,2003
- Myasthenia gravis.2002
- The C5a complement activation peptide increases IL-1β and IL-6 release from amyloid-β primed human monocytes: implications for Alzheimer’s diseaseJournal of Neuroimmunology, 2000
- Diagnostic significance of IgG, C3, and C9 at the limb muscle motor end‐plate in minimal myasthenia gravisNeurology, 1989